CYC
$91M—
Cyclopharm
Biotechnology · Diagnostics
Nuclear medicine Technegas lung ventilation diagnostic
Cash data from Dec 2025 4CFigures from ASX filings · not financial advice
[ VITALS ]
Cash on Hand
$6.6M
Dec 2025 4C
Runway
—Based on Dec 2025 4C
Market Cap
$91M
Burn Rate
—
Dec 2025 4C
Shares Outstanding
126M
Pipeline Assets
2
Latest Insight(1)
27 Mar 20263M Price
CYC.ASX$0.725-18.5% 3M
Low $0.670High $1.230
Pipeline Assets (2)
Technegas PlusLung ventilation imaging (next-gen generator)
NDA FiledTechnegasLung ventilation imaging (nuclear medicine)
ApprovedDiscovery
Preclinical
Ph 1
Ph 1/2
Ph 2
Ph 2/3
Ph 3
NDA
Approved
Technegas Plus
Capital Raises & Buybacks
show_chart
No capital raise or buyback data
Director Options & Rights
Director
Outstanding
Ex. Price
Expiry
No option data entered yet
expand_moreClinical Publications
Peer-reviewed papers & conference abstracts via PubMed
1 paper
Clinical Publications
Peer-reviewed papers & conference abstracts via PubMed
Clin Nucl Med2026-04· Technegas
Catalysts (2)
NIH and federal hospital Technegas expansion
UpcomingConfirmedremoveMed30 June 2026
Technegas 250-300 US installations target
UpcomingExpectedarrow_upwardHigh31 Dec 2026
| Event | Type | Confidence | Impact | Date | Status |
|---|---|---|---|---|---|
| NIH and federal hospital Technegas expansion Purchase order received from NIH Bethesda. Opens federal/VA hospital channel | commercial milestone | Confirmed | removeMed |
Delivery Consistency Index
Historical delivery and spending consistency — data is limited for recently added companies.
Track record will build as data accumulates — we need completed catalysts with original guidance dates, or at least two quarterly 4Cs, before scoring kicks in.